The profile of leucocytes, CD3+, CD4+, and CD8+ T cells, and cytokine concentrations in peripheral blood of children with acute asthma exacerbation

Thuy Nguyen-Thi-Dieu¹, Huong Le-Thi-Thu² and Sy Duong-Quy³,⁴,⁵

Abstract
Objective: To determine the leucocyte profile and cytokine concentrations in the peripheral blood of children with an acute asthma exacerbation (AAE).

Methods: This descriptive, cross-sectional study enrolled paediatric patients admitted to hospital for AAE. The severity of AAE was assessed using the paediatric asthma score (PAS). Peripheral blood samples were collected for automatic quantification of white blood cell counts, CD3+, CD4+, and CD8+ T cells populations by flow cytometry and cytokine concentrations by flow cytometry-assisted immunoassay.

Results: A total of 127 children with AAE and 30 healthy control subjects were included in the study. The proportion of paediatric patients with decreased CD3+, CD4+ and CD8+ T cells was significantly higher in those with severe AAE compared with those with mild-to-moderate AAE. The concentrations of interleukin (IL)-2, IL-8, IL-12, and IL-4 in paediatric patients with rhinovirus infection were significantly higher than in those without rhinovirus infection. IL-2, IL-4, IL-6, TNF-α, and GM-CSF concentrations during AAE were significantly lower than control. IL-5 and IL-13 concentrations during AAE were significantly higher than control.

Conclusions: The decrease of CD3+, CD4+, CD8+ T cells and IL-2, IL-4, IL-6, TNF-α, and GM-CSF combined with the increase of IL-5 and IL-13, were associated with AAE in children with asthma.
Keywords
Asthma, exacerbation, hypereosinophilia, cytokine, CD++ T cells

Date received: 7 July 2016; accepted: 1 November 2016

Introduction
Asthma is a chronic respiratory disease characterized by airway inflammation and bronchial hyperresponsiveness associated with reversible airway obstruction. In children, asthma is a common chronic respiratory disease. In recent decades, the prevalence of asthma in children has increased constantly worldwide. Increasing evidence suggests that it might be due to the interaction between different factors such as the environment (e.g. global urbanization and air pollution) and a genetic disorder. Many inflammatory cells, cellular components, and signalling pathways are involved in the pathogenesis of asthma. Among them, the role of T lymphocytes with their inflammatory cytokines has been discussed widely.

Cytokines are preinflammatory and inflammatory peptides produced mainly from T lymphocytes and other cells such as eosinophils, macrophages, and fibroblasts. Cytokines play a crucial role in modulating airway inflammation and in remodelling the airway structure of patients with asthma, especially in severe or refractory asthma. The features of inflammatory cells and cytokines in the airways might define the clinical and pathological phenotypes of asthma patients. Recently, the role of cytokines related to T lymphocytes in uncontrolled asthma, especially in viral infection-induced asthma exacerbation, has been demonstrated. However, their role in children with acute asthma exacerbation (AAE) has not been well clarified.

This present study aimed to characterize the inflammatory cell profile and cytokine concentrations in the peripheral blood of children with asthma during AAE.

Patients and methods

Patient population
This descriptive, cross-sectional study consecutively enrolled children with AAE who were hospitalized in the Department of Respiratory Diseases, National Hospital of Paediatrics, Hanoi, Vietnam between February 2014 and April 2015. The inclusion criteria were as follows: (i) <17 years old; (ii) hospitalized for AAE where the diagnosis of AAE was based on the criteria recommended by the Global Initiative for Asthma. The exclusion criteria were as follows: (i) concomitant presence of other severe cardiovascular or gastroenterological diseases, renal or hepatic dysfunction; (ii) concomitant presence of acute respiratory distress syndrome or severe pneumonia.

A group of healthy children in the same age group who received a routine health check at the National Hospital of Paediatrics were used as the control group.

This study was approved by the Medical Ethics Committee of the National Hospital of Paediatrics (no. 965B/BV.NTW-VNCSKTE). The parents or legal guardians of the children with AAE and the healthy control subjects provided written informed consent before the start of the study.

Diagnosis of asthma severity
The diagnosis of asthma was based on international recommendations for children ≥ 5 years old. The severity of AAE was assessed according to the paediatric asthma score (PAS). The examination consisted of five components: (i) respiratory rate; (ii) oxygen requirement; (iii) respiratory muscle retractions; (iv) auscultation; and (v) dyspnoea. Each component was scored from 1
to 3 according to the severity of the symptoms as follows: (i) respiratory rate: \( \leq 34 \) (2–3 years), \( \leq 30 \) (4–5 years), \( \leq 26 \) (6–12 years), \( \leq 23 \) (>12 years) = 1; 35–39 (2–3 years), 31–35 (4–5 years), 27–30 (6–12 years), \( \leq 24-27 \) (>12 years) = 2; \( \geq 40 \) (2–3 years), \( \geq 36 \) (4–5 years), \( \geq 31 \) (6–12 years), \( \geq 28 \) (>12 years) = 3; (ii) oxygen requirements (peripheral capillary oxygen saturation [SpO₂]): >95% on room air = 1; 90–95% on room air = 2; <90% on room air or on any oxygen = 3; (iii) respiratory muscle retractions: none or intercostal = 1; intercostal and substernal = 2; intercostal, substernal and supraclavicular = 3; (iv) auscultation: normal breath sounds to end-expiratory wheezing only = 1; expiratory wheezing = 2; inspiratory and expiratory wheezing = 3; (v) dyspnoea: speaks in sentences = 1; speaks in partial or short sentences = 2; speaks in single words/short phrases/grunting = 3. The total scores ranged from 5–7 for mild asthma exacerbation, 8–11 for moderate asthma exacerbation and 12–15 for severe asthma exacerbation.

**Quantifying white blood cells**

Blood samples (2 ml) were collected through venipuncture and drawn into tubes containing 10% ethylenediaminetetra-acetic acid. All blood samples were kept refrigerated during a short storage period and immediate transportation to the laboratory. The white blood cells in peripheral blood samples were counted automatically using an ADVIA® 2120i Haematology System (Siemens Healthcare, Erlangen, Germany) by the Haematology Laboratory of the National Hospital of Paediatrics. The normal value of leucocytes in children classified by age group was: \( \leq 2 \) years: \(<10.6 \times 10^3/mm^3\) (6–17 \( \times 10^3/mm^3\)); \( \leq 4 \) years: \(<9.1 \times 10^3\) (5.5–15.5 \( \times 10^3/mm^3\)); \( \leq 6 \) years: \(8.5 \times 10^3/mm^3\) (5.0–14.5 \( \times 10^3/mm^3\)); \( \leq 8 \) years: \(8.3 \times 10^3/mm^3\) (4.5–13.5 \( \times 10^3/mm^3\)); \( \leq 10 \) years: \(8.1 \times 10^3/mm^3\) (4.5–13.5 \( \times 10^3/mm^3\)).

**Quantifying CD3+, CD4+ and CD8+ cells by flow cytometry**

Flow cytometry was used to determine the T lymphocyte subtypes (CD3+, CD4+ and CD8+) in peripheral blood by the Haematology Laboratory of the National Hospital of Paediatrics. A 50-μl sample of peripheral blood was mixed with 20 μl of fluorescent conjugated monoclonal antibodies (fluorescein isothiocyanate mouse anti-human CD3; phycoerythrin/Cy7 mouse anti-human CD4; allophycocyanin/Cy7 mouse anti-human CD8; Abcam, Cambridge, UK) and incubated at room temperature for 15 min. Then 450 μl of BD FACSTM Lysing solution 1 \( \times \) (BD Biosciences, San Jose, CA, USA) was added to each sample, mixed and incubated at room temperature in the dark for 15 min. The fluorescent-labelled leucocytes were passed through a BD FACSCantoTM II flow cytometer (BD Biosciences). Based on the size, nuclear density and fluorescent colours, each individual cell population was identified and quantified. The normal value of the T lymphocyte subtypes in children, classified by age group, are: CD3+ (cells/mm³): <1 year: \( \geq 2500\), 1–2 years: \( \geq 2100\), >2 and \( \leq 6\) years: \( \geq 1400\), >6 and \( \leq 12\) years: \( \geq 1200\); CD4+ (cells/mm³): <1 year: \( \geq 1400\), 1–2 years: \( \geq 1300\), >2 and \( \leq 6\) years: \( \geq 700\), >6 and \( \leq 12\) years: \( \geq 650\); CD8+ (cells/mm³): <1 year: \( \geq 500\), 1–2 years: \( \geq 620\), >2 and \( \leq 6\) years: \( \geq 490\), >6 and \( \leq 12\) years: \( \geq 370\).

**Quantifying cytokines by flow cytometry-assisted immunoassay**

Venous blood samples (2 ml) from patients and control subjects were drawn into tubes without anticoagulant and transferred directly to the laboratory for analysis. Quantification of the cytokine concentration was performed in the Immunology Laboratory of the Military Medical Academy 103, Hanoi, Vietnam.
Monoclonal antibodies (Bio-Rad, Hercules, CA, USA) were used for eleven cytokines related to type 1 helper T (Th1) cells (interleukin [IL]-2, IL-8, IL-12, interferon [IFN]-γ, and tumour necrosis factor [TNF]-α), regulatory T cells (T<sub>reg</sub>; IL-10), and type 2 helper T (Th2) cells (IL-4, IL-5, IL-6, IL-13, and granulocyte-macrophage colony-stimulating factor [GM-CSF]; Bio-Plex® human cytokines; Bio-Rad). The tests were conducted using a flow cytometry-assisted immunoassay provided by the Bio-Plex® Multiplex System (Bio-Rad). Blood samples without anticoagulant were placed in an incubator (37°C) for 30 min, then centrifuged at 1000 g for 5 min at 4°C (ScanSpeed 416; LaboGene, Lynge, Denmark). After removing the fibrin plug, the samples were centrifuged again at 4°C for 15 min at 10 000 g (ScanSpeed 416; LaboGene) and prepared for freezing. All samples were stored at −80°C until tested. Cytokines were detected by immunofluorescence using the sandwich technique on the surface of polystyrene microspheres in accordance with the manufacturer’s protocol (Bio-Rad). The reduced immunoglobulin G was purified and coupled to the activated microspheres. Microspheres were incubated with biotinylated antibodies for IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, IFN-γ, TNF-α and GM-CSF overnight with shaking at room temperature. Microspheres were then washed, resuspended in 1× phosphate-buffered saline (PBS; pH 7.4), then transferred to tubes for acquisition on the flow cytometer (Bio-Plex® 200 System; Bio-Rad). Based on the density of the fluorescence emitted from the microspheres incubated with known concentrations of cytokines, the cytokines in the study samples were quantified using Bio-Plex Manager™ Software (Bio-Rad). For each cytokine, the curve fit parameters were established with international cytokine standards and stored in a post analysis database file. These master curves were used to analyse the immunoassay data.

Statistical analyses
All statistical analyses were performed using the SPSS® statistical package, version 22.0 (SPSS Inc., Chicago, IL, USA) for Windows®. Qualitative variables were expressed as numbers or percentages. Quantitative variables were presented as mean ± SD or median (min – max). The standard distribution was tested by using the Skewness–Kurtosis test. The Mann–Whitney U-test was used to evaluate the correlation between cytokine levels, CD cell counts, and the severity of asthma. The Z-test was used to compare the frequency between groups. The Kruskall–Wallis test was used for multiple comparisons. A P-value < 0.05 was considered statistically significant.

Results
The study enrolled 127 children with AAE with a mean ± SD age of 58 ± 38 months (range 7–165 months) who were hospitalized in the National Hospital of Paediatrics, Hanoi, Vietnam and 30 healthy control subjects with a mean ± SD age of 56 ± 44 months (range 1–168 months). There was no significant difference between the mean age or the age distribution between the two groups (data not shown). The clinical and demographic characteristics of the children with AAE are shown in Table 1. The majority of the patients with AAE were 2–5 years old, with a predominance of males. The serodiagnosis of rhinovirus was positive in 64 of 117 (54.7%) patients. Sixty-three of 127 (49.6%) patients had severe asthma exacerbation compared with 52 (40.9%) patients with moderate and 12 (9.4%) with mild asthma exacerbation (Table 1). There was no significant difference in the length of hospital stay between children with mild, moderate and severe AAE based on PAS.

The results of peripheral blood analysis showed that 103 of 127 (81.1%) patients had
increased leucocytes compared with 24 of 127 (18.9%) patients who had normal values (Table 2). A total of 38 of 122 (31.1%) patients had increased eosinophils compared with 84 of 122 (68.9%) patients who had normal values. A total of 84 of 127 (66.1%) patients had increased neutrophils compared with 43 of 127 (33.9%) patients who had normal values. The percentage of patients with increased leucocytes varied with the severity of AAE. It was highest in patients with severe asthma exacerbation in comparison with mild or moderate asthma exacerbation (87.3% \( n = 55 \) versus 66.7% \( n = 8 \) and 76.9% \( n = 40 \), respectively), but it was only significantly different between the mild and severe asthma exacerbation groups \( (P < 0.05) \). The percentage of

| Characteristics          | Frequency\(^a\) | Proportion (%) |
|--------------------------|-----------------|----------------|
| Age                      |                 |                |
| <2 years                 | 24              | 18.9           |
| 2–5 years                | 58              | 45.7           |
| >5 years                 | 45              | 35.4           |
| Sex                      |                 |                |
| Male                     | 83              | 65.4           |
| Female                   | 44              | 34.6           |
| Atopic allergy           |                 |                |
| Eczema                   | 46              | 37.4           |
| Allergic rhinitis        | 86              | 69.9           |
| Food                     | 12              | 9.8            |
| Others                   | 13              | 10.6           |
| Rhinovirus infection     |                 |                |
| Positive                 | 64              | 54.7           |
| Negative                 | 53              | 45.3           |
| PAS                      |                 |                |
| Mild                     | 12              | 9.4            |
| Moderate                 | 52              | 40.9           |
| Severe                   | 63              | 49.6           |
| Length of hospital stay  |                 |                |
| Classified by days       |                 |                |
| 1–3 days                 | 41              | 32.3           |
| >3–5 days                | 59              | 46.5           |
| >5 days                  | 27              | 21.3           |
| Classified by PAS        |                 |                |
| Mild                     | Days            | Statistical significance\(^b\) |
|                         | 5.0 ± 1.5       | NS             |
| Moderate                 | 4.5 ± 2.0       |                |
| Severe                   | 5.0 ± 2.0       |                |

Data presented as \( n \) of patients (%) or mean ± SD.

\(^a\)Baseline data missing for some patients.

\(^b\)Kruskall–Wallis test.

PAS, paediatric asthma score (mild 5–7, moderate 8–11, severe 12–15); NS, no significant between-group differences \( (P \geq 0.05) \).
patients with increased eosinophils was not significantly different between the three asthma exacerbation groups. The percentage of patients with severe asthma exacerbation and an increased neutrophil count was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The proportion of patients with decreased CD3+ T cells in the severe AAE group was significantly higher than for patients with mild or moderate asthma exacerbation (76.2% [n = 48] versus 41.7% [n = 5] and 59.6% [n = 31], respectively; P < 0.01 and P < 0.05, respectively).

The concentration of IL-2 during AAE was not significantly different compared with those after the exacerbation period. The concentrations of IL-2 during and after AAE were significantly lower than that in the control subjects (P < 0.001; Table 4). The concentrations of IL-10, IL12 and INF-γ during and after AAE were not significantly different compared with control subjects. The concentration of TNF-α during AAE was lower than that after AAE and when compared with the control subjects, but a significant difference was only found in TNF-α concentrations during and after AAE compared with the control subjects (P < 0.05).

The concentration of IL-4 during AAE was significantly lower than after AAE and the concentrations of IL-4 during and after AAE were significantly lower compared with the control subjects (P < 0.001 for both comparisons; Table 4). The concentration of IL-6 during AAE was significantly lower than after AAE and compared with the control subjects (P < 0.05 for both comparisons). The

| Table 2. Leucocyte profile classified by the paediatric asthma score (PAS) for the acute asthma exacerbation. |
|---------------------------------------------------|---------------------------------|------------------|------------------|-----------------|-----------------|
| Cell types                                        | PAS                             | Mild (%)         | Moderate (%)     | Severe (%)      | Total (%)       |
| Leucocytes                                        | Normal                          | 4 (33.3)         | 12 (23.1)        | 8 (12.7)        | 24 (18.9)       |
| n = 127                                          | Increased                       | 8 (66.7)         | 40 (76.9)        | 55 (87.3)       | 103 (81.1)      |
| Eosinophils                                       | Normal                          | 7 (58.3)         | 35 (70.0)        | 42 (70.0)       | 84 (68.9)       |
| n = 122                                          | Increased                       | 5 (41.7)         | 15 (30.0)        | 18 (30.0)       | 38 (31.1)       |
| Neutrophils                                       | Normal                          | 7 (58.3)         | 21 (40.4)        | 15 (23.8)       | 43 (33.9)       |
| n = 127                                          | Increased                       | 5 (41.7)         | 31 (59.6)        | 48 (76.2)       | 84 (66.1)       |

Data presented as n of patients (%).

Kruskall–Wallis test; *moderate versus mild; **severe versus mild; ***severe versus moderate.

>10 × 10³/mm³; >4%; >45% for children <5 years and >65% for children ≥5 years.

*Data missing for five patients.

Paediatric asthma score: mild 5–7, moderate 8–11, severe 12–15.

NS, no significant between-group difference (P ≥ 0.05).
Table 3. T lymphocyte profile classified by the paediatric asthma score (PAS) for the acute asthma exacerbation.

| T lymphocyte subgroups | PAS          | Statistical significance<sup>a</sup> | Mild-to-moderate | Severe | Total |
|------------------------|--------------|---------------------------------------|------------------|--------|-------|
| CD3<sup>+</sup>        | Normal       |                                       | 16 (76.2)        | 15 (50.0) | 31 (60.8) |
| n = 51                 | Decreased<sup>b</sup> |                                       | 5 (23.8)         | 15 (50.0) | 20 (39.2) |
| CD4<sup>+</sup>        | Normal       |                                       | 13 (65.0)        | 14 (46.7) | 27 (54.0) |
| n = 50                 | Decreased<sup>c</sup> |                                       | 7 (35.0)         | 16 (53.3) | 23 (46.0) |
| CD8<sup>+</sup>        | Normal       |                                       | 20 (95.2)        | 21 (72.4) | 41 (82.0) |
| n = 50                 | Decreased<sup>d</sup> |                                       | 1 (4.8)          | 8 (27.6)  | 9 (18.0)  |

Data presented as n of patients (%).

<sup>a</sup>Z-test; severe versus mild-to-moderate asthma exacerbation.

<sup>b</sup>Decreased CD3<sup>+</sup> T cells: <2500 for <1 year, <2100 for 1–2 years, <1400 for >2 and ≤6 years, <1200 for >6 and ≤12 years, <100 for >12 years.

<sup>c</sup>Decreased CD4<sup>+</sup> T cells: <1400 for <1 year, <1300 for 1–2 years, <700 for >2 and ≤6 years, <650 for >6 and ≤12 years, <530 for >12 years.

<sup>d</sup>Decreased CD8<sup>+</sup> T cells: <500 for <1 year, <620 for 1–2 years, <490 for >2 and ≤6 years, <370 for >6 and ≤12 years, <330 for >12 years.

Table 4. Profile of cytokine levels in patients during and after the acute asthma exacerbation compared with healthy control subjects.

| Cytokines                          | Patients with acute asthma exacerbation | Control group | Statistical significance<sup>a</sup> |
|------------------------------------|-----------------------------------------|--------------|-------------------------------------|
|                                    | During, n = 127                          | After, n = 59| n = 30                              |
| IL-2                               | 0.16 (0.05–44.02)                       | 0.16 (0.11–5.90) | 0.51 (0.11–67.86) | NS<sup>*</sup> |
| IL-8                               | 5.07 (1.50–88.37)                       | 4.11 (2.23–346.80) | 5.07 (0.75–29.62) | P < 0.001** |
| IL-10                              | 2.35 (0.01–399.78)                      | 2.21 (0.32–10.27) | 1.52 (0.30–43.00) | NS<sup>***</sup> |
| IL-12                              | 0.01 (0.01–11.98)                       | 0.01 (0.01–5.82) | 0.01 (0.01–1.83) | NS<sup>***</sup> |
| IFN-γ                              | 12.41 (0.21–1056.32)                    | 12.41 (2.77–170.43) | 12.40 (2.76–1477.20) | NS<sup>***</sup> |
| TNF-α                              | 0.43 (0.21–249.91)                      | 0.67 (0.10–393.92) | 1.46 (0.32–44.46) | NS<sup>*</sup> |

Cytokines related to type 2 helper T cells, pg/ml

| Cytokines | During, n = 127 | After, n = 59 | n = 30 | Statistical significance<sup>a</sup> |
|-----------|-----------------|--------------|--------|-------------------------------------|
| IL-4      | 0.02 (0.01–2.80) | 0.16 (0.11–5.9) | 0.51 (0.11–67.86) | P < 0.001*** |
| IL-5      | 1.49 (0.01–2.80) | 0.02 (0.01–1.11) | 0.08 (0.02–14.58) | P < 0.001<sup>*,</sup> |
| IL-6      | 0.30 (0.03–40.90) | 0.97 (0.03–16.62) | 1.03 (1.03–36.63) | NS<sup>y</sup> |
| IL-13     | 2.08 (0.07–33.88) | 0.10 (0.10–5.87) | 1.24 (0.09–5.89) | P < 0.001<sup>*,</sup> |
| GM-CSF    | 0.91 (0.21–717.85) | 0.91 (0.22–109.51) | 5.73 (0.91–198.30) | NS<sup>*</sup> |

Data presented as median (min–max).

<sup>a</sup>Kruskall–Wallis test; versus after acute asthma exacerbation; **during and after acute asthma exacerbation versus control; 2 during versus control group; *after versus control; NS, no significant between-group difference (P ≥ 0.05). IL, interleukin; IFN, interferon; TNF, tumour necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
concentrations of GM-CSF during and after AAE were significantly lower compared with the control subjects \((P < 0.001)\). The concentration of IL-13 during AAE was significantly higher than after AAE and compared with the control subjects \((P < 0.001\) for both comparisons). The concentration of IL-13 after AAE was significantly lower compared with the control subjects \((P < 0.001)\).

The concentrations of IL-2, IL-8, IL-12, and IL-4 in patients with AAE and positive rhinovirus infection were significantly higher than after AAE and compared with the control subjects \((P < 0.001\) for both comparisons). The concentration of IL-13 after AAE was significantly lower compared with the control subjects \((P < 0.001)\).

The concentrations of cytokines related to \(T_{h1}\) and \(T_{reg}\) (IL-2, IL-8, IL-10, INF-\(\gamma\), and TNF-\(\alpha\)) were not significantly different between patients with mild, moderate and severe AAE based on PAS (Table 6). The concentrations of cytokines related to \(T_{h2}\) (IL-4, IL-5, IL-6, IL-13, and GM-CSF) were not significantly different between patients with mild, moderate and severe AAE based on PAS.

**Discussion**

The results of the present study showed that:
(i) paediatric patients with AAE had significantly increased leucocyte counts with a predominance of high neutrophil counts especially in those with severe AAE based on the PAS; (ii) the proportion of paediatric patients with decreased CD3\(+/CD4+/CD8+\) T cells in those with severe AAE was significantly higher than in paediatric patients with mild-to-moderate AAE; (iii) the changes in cytokine concentrations depended on AAE, rhinovirus infection, but not on AAE severity based on the PAS.

The results of this present study showed that nearly 55% of paediatric patients with

**Table 5. Cytokine concentrations in patients with or without rhinovirus (RV) infection.**

| Cytokines | RV\(+\) \(n = 64\) | RV\(–\) \(n = 53\) | Statistical significance\(^{a}\) |
|-----------|------------------|------------------|------------------|
| IL-2      | 0.25 (0.10–44.02) | 0.16 (0.05–38.78) | \(P < 0.05\) |
| IL-8      | 5.97 (2.08–88.37) | 3.46 (1.50–21.96) | \(P < 0.05\) |
| IL-10     | 2.35 (0.03–48.61) | 2.75 (0.01–399.78) | NS |
| IL-12     | 0.81 (0.01–11.98) | 0.01 (0.01–5.59) | \(P < 0.05\) |
| INF-\(\gamma\) | 12.41 (0.21–1056.32) | 12.41 (2.43–642.50) | NS |
| TNF-\(\alpha\) | 0.43 (0.21–230.19) | 0.63 (0.27–249.91) | NS |
| IL-5      | 2.11 (0.07–9.49) | 0.90 (0.05–7.87) | NS |
| IL-6      | 1.03 (0.03–7.24) | 0.06 (0.03–40.09) | NS |
| IL-13     | 3.01 (0.07–33.88) | 1.67 (0.10–5.87) | NS |
| GM-CSF    | 5.73 (0.21–717.85) | 0.91 (0.21–137.42) | NS |

Data presented as median (min–max).

\(^{a}\)Mann–Whitney U-test.

IL, interleukin; IFN, interferon; TNF, tumour necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; NS, no significant between-group difference \((P > 0.05)\).
AAE had a rhinovirus infection, which was confirmed by a serodiagnostic test. Almost half of the paediatric patients had severe AAE. The present study also showed that 81.1% of patients had increased leukocyte counts, 66.1% had increased neutrophil counts and 31.1% had increased eosinophil counts during AAE. None of the 127 paediatric patients had severe pneumonia. These current results suggest that a high neutrophil count without pneumonia might be a characteristic of asthmatic children with AAE. It also suggests that asthmatic children with a rhinovirus infection might have increased leucocyte counts in the AAE period. Previous studies showed that rhinovirus infection increased lower airway responsiveness in allergic and asthmatic subjects.\textsuperscript{17,18}

The present study showed that during AAE, the CD3\(^+\), CD4\(^+\) and CD8\(^+\) T cells were normal or decreased in all asthmatic paediatric patients. Fifty percent of paediatric patients with severe AAE had decreased CD3\(^+\) T cells, 53.3% had decreased CD4\(^+\) T cells, and 27.6% had decreased CD8\(^+\) T cells. The proportion of paediatric patients with decreased CD3\(^+\), CD4\(^+\) and CD8\(^+\) T cells in the group with severe AAE was significantly higher than that in the group with mild-to-moderate AAE. This result suggests that the reduction of CD3\(^+\), CD4\(^+\) and CD8\(^+\) T cells might be a good marker for AAE in asthmatic children. However, the T lymphocyte profile in asthmatic children during and after AAE has not been well clarified. A previous study found a reduction in the percentage of CD4\(^+\) producing IFN-\(\gamma\) in asthmatic children.\textsuperscript{11} In contrast, another study demonstrated that the percentage of CD8\(^+\) IFN-\(\gamma\) cells was increased in the period after AAE.\textsuperscript{19} Research demonstrated that the percentage of CD3\(^+\) cells producing related cytokines was not significantly different

| Cytokines | PAS | Mild \(n = 12\) | Moderate \(n = 52\) | Severe \(n = 63\) |
|----------|-----|----------------|----------------|----------------|
| **Cytokines related to type 1 helper T cells and regulatory T cells, pg/ml** | | | | |
| IL-2 | 0.16 (0.05–13.86) | 0.16 (0.05–44.02) | 0.16 (0.10–15.99) |
| IL-8 | 5.20 (2.68–21.96) | 5.01 (2.08–21.90) | 5.07 (1.50–88.37) |
| IL-10 | 2.06 (0.07–78.07) | 2.71 (0.01–57.97) | 2.19 (0.03–48.61) |
| IL-12 | 0.45 (0.01–11.98) | 0.01 (0.01–8.63) | 0.02 (0.01–9.56) |
| INF-\(\gamma\) | 12.41 (2.43–461.45) | 22.41 (2.43–642.50) | 12.41 (0.21–1056.32) |
| TNF-\(\alpha\) | 0.33 (0.32–95.70) | 0.43 (0.27–249.91) | 0.43 (0.21–230.19) |
| **Cytokines related to type 2 helper T cells, pg/ml** | | | | |
| IL-4 | 0.01 (0.01–1.85) | 0.02 (0.01–1.89) | 0.02 (0.01–2.80) |
| IL-5 | 0.82 (0.28–8.17) | 1.81 (0.07–6.85) | 1.49 (0.05–9.49) |
| IL-6 | 0.53 (0.03–4.85) | 0.06 (0.03–40.90) | 0.72 (0.03–30.20) |
| IL-13 | 3.70 (0.19–4.87) | 1.81 (0.60–7.04) | 2.08 (0.07–33.88) |
| GM-CSF | 0.22 (0.21–233.21) | 0.91 (0.21–188.38) | 0.91 (0.21–717.85) |

Data presented as median (min–max).
*Kruskall–Wallis test; no significant between-group differences (\(P \geq 0.05\)).
Paediatric asthma score: mild 5–7, moderate 8–11, severe 12–15.
IL, interleukin; IFN, interferon; TNF, tumour necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.
between atopic, non-asthma and control subjects. Similarly, another study demonstrated that the percentage of total CD3+ T cells in peripheral blood was similar in asthmatic patients and healthy control subjects.

The pathophysiology of asthma is characterized by airway inflammation and its severity depends on the inflammatory response. Previous studies demonstrated the significant role of Th2 cells producing IL-4, IL-5, and IL-13, in the pathology of allergic asthma. The concentration of IL-4 during AAE was significantly lower than after AAE and the concentrations of IL-4 during and after AAE were significantly lower compared with the control subjects. The concentration of IL-6 during AAE was significantly lower than after AAE and compared with the control subjects. The concentration of IL-5 in asthma patients during AAE was significantly higher than that after AAE and compared with the healthy control subjects. This suggests that there was a dysregulation of these cytokines during AAE in children. IL-4 and IL-5 play an important role in mediating the progression of allergic airway inflammation and are involved in the differentiation of T cells. In patients with allergic asthma, IL-4 is increased in the peripheral blood and bronchoalveolar lavage and it also plays a crucial role in airway hyperresponsiveness. The role of IL-4 in children with asthma has been demonstrated by previous studies. A previous study showed that, in children with asthma, the concentration of IL-4 depended on the severity of the disease. However, the role of IL-4, IL-5, and IL-13 in AAE has not been clearly demonstrated. The present study showed that the concentration of IL-13 was significantly increased in asthmatic children during the AAE period compared with after the AAE and compared with the control subjects. Hence, the discordant changes of IL-13 and GM-CSF during asthma crisis might be a relevant marker for AAE in children. In the airway, IL-13 induces the contraction of smooth muscle cells and hypersecretion of sputum, especially in patients with asthma. GM-CSF plays an important role in severe asthma exacerbation and drug resistance.

The results of the present study showed that the concentration of TNF-α during and after AAE was significantly lower than that in control subjects. Previous studies showed that the concentration of TNF-α was significantly increased in children with severe and poorly controlled asthma; and that TNF-α inhibitors could be a potential treatment for refractory asthma. In the present study, the concentration of IFN-γ did not change during and after AAE and it was not different compared with the concentration in control subjects. In the present study, the concentrations of IL-2, IL-4, IL-8, and IL-12 were significantly higher in paediatric patients with rhinovirus infection compared with those patients without rhinovirus infection. This result was similar to previous studies. The present study showed that the concentrations of all studied cytokines were not significantly different between mild, moderate and severe AAE as evaluated by PAS in asthmatic children.

In conclusion, AAE remains a challenge for respiratory care in children. The results of the present study showed that a reduction in CD+ T cells and IL-2, IL-4, IL-6, TNF-α, and GM-CSF concentrations, combined with an increase of IL-5 and IL-13 concentrations, were associated with AAE in children with asthma. However, more studies in this field are necessary to enrich our knowledge about the role of the inflammatory profile and pathways in children with asthma during acute exacerbation.

Declaration of conflicting interest
The authors declare that there are no conflicts of interest.
Funding
This study was supported by a grant from the National Foundation for Science & Technology Development (NAFOSTED no. 106.99-2012.12).

References
1. World Health Organization. Chronic respiratory diseases. Asthma, www.who.int/respiratory/asthma/en/ (2016, accessed 12 March 2016).
2. Global Initiative for Asthma, www.globalasthmareport.org/resources/Global_Asthma_Report_2014.pdf (2014, accessed 21 February 2015).
3. Spycher BD, Henderson J, Granell R, et al. Genome-wide prediction of childhood asthma and related phenotypes in a longitudinal birth cohort. J Allergy Clin Immunol 2012; 130: 503–509.
4. Sabounchi S, Bollyky J and Nadeau K. Review of environmental impact on the epigenetic regulation of atopic diseases. Curr Allergy Asthma Rep 2015; 15: 33.
5. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet 2008; 372: 1107–1119.
6. Larché M, Robinson DS and Kay AB. The role of T lymphocytes in the pathogenesis of asthma. J Allergy Clin Immunol 2003; 111: 450–463.
7. Abdulamir AS, Hafidh RR, Abubakar F, et al. Changing survival, memory cell compartment, and T-helper balance of lymphocytes between severe and mild asthma. BMC Immunol 2008; 9: 73.
8. Hamid Q and Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009; 71: 489–507.
9. Moldoveanu B, Otmiashi P, Jani P, et al. Inflammatory mechanisms in the lung. J Inflamm Res 2009; 2: 1–11.
10. Murdoch JR and Lloyd CM. Chronic inflammation and asthma. Mutat Res 2010; 690: 24–39.
11. Machura E, Mazur B, Rusek-Zychma M, et al. Cytokine production by peripheral blood CD4+ and CD8+ T cells in atopic childhood asthma. Clin Dev Immunol 2010; 2010: 606139.
12. Newcomb DC, Sajjan US, Nagarkar DR, et al. Cooperative effects of rhinovirus and TNF-[alpha] on airway epithelial cell chemokine expression. Am J Physiol Lung Cell Mol Physiol 2007; 293: L1021–L1028.
13. Brown SD, Brown LA, Stephenson S, et al. Characterization of a high TNF-α phenotype in children with moderate-to-severe asthma. J Allergy Clin Immunol 2015; 135: 1651–1654.
14. Global Initiative for Asthma, http://ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf (accessed 12 April 2016).
15. Smith SR, Baty JD and Hodge D 3rd. Validation of the pulmonary score: an asthma severity score for children. Acad Emerg Med 2002; 9: 99–104.
16. Ducharme FM, Chalut D, Plotnick L, et al. The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. J Pediatr 2008; 152: 476–480.
17. Brooks GD, Buchta KA, Swenson CA, et al. Rhinovirus-induced interferon-gamma and airway responsiveness in asthma. Am J Respir Crit Care Med 2003; 168: 1091–1094.
18. Gern JE, Calhoun W, Swenson C, et al. Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. Am J Respir Crit Care Med 1997; 155: 1872–1876.
19. Calderon C, Rivera L, Hutchinson P, et al. T-cell cytokine profiles are altered in childhood asthma exacerbation. Respir Res 2009; 14: 264–269.
20. Brown V, Warke TJ, Shields MD, et al. T cell cytokine profiles in childhood asthma. Thorax 2003; 58: 311–316.
21. Bakakos P, Pickard C, Smith JL, et al. TCR usage and cytokine expression in peripheral blood and BAL T cells. Clin Exp Immunol 2002; 128: 295–301.
22. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388–395.
23. Hsieh CS, Heimberger AB, Gold JS, et al. Differential regulation of T helper phenotype development by interleukins 4 and 10 in an alpha beta T-cell-receptor transgenic
system. *Proc Natl Acad Sci U S A* 1992; 89: 6065–6069.

24. Seder RA, Paul WE, Davis MM, et al. The presence of interleukin 4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice. *J Exp Med* 1992; 176: 1091–1098.

25. Daher S, Santos LM, Solé D, et al. Interleukin-4 and soluble CD23 serum levels in asthmatic atopic children. *J Invest Allergol Clin Immunol* 1995; 5: 251–254.

26. Walker C, Bauer W, Braun RK, et al. Activated T cells and cytokines in bronchial lavages from patients with various lung diseases associated with eosinophilia. *Am J Respir Crit Care Med* 1994; 150: 1038–1048.

27. Shi HZ, Deng JM, Xu H, et al. Effect of inhaled interleukin-4 on airway hyperreactivity in asthmatics. *Am J Respir Crit Care Med* 1998; 157(6 Pt 1): 1818–1821.

28. Akçakaya N, Sözer V, Çokuğraş H, et al. Preliminary study on IL4 levels in extrinsic atopic asthmatic children. *Turk J Pediatr* 1994; 36: 105–110.

29. Hoekstra MO, Hoekstra Y, De Reus D, et al. Interleukin-4, interferon-gamma and interleukin-5 in peripheral blood of children with moderate atopic asthma. *Clin Exp Allergy* 1997; 27: 1254–1260.

30. Renauld JC. New insights into the role of cytokines in asthma. *J Clin Pathol* 2001; 54: 577–589.

31. Takatsu K and Nakajima H. IL-5 and eosinophilia. *Curr Opin Immunol* 2008; 20: 288–294.

32. Chiba Y, Nakazawa S, Todoroki M, et al. Interleukin-13 augments bronchial smooth muscle contractility with an up-regulation of RhoA protein. *Am J Respir Cell Mol Biol* 2009; 40: 159–167.

33. Berry MA, Parker D, Neale N, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. *J Allergy Clin Immunol* 2004; 114: 1106–1109.

34. Siroix V, Basagaña X, Boudier A, et al. Identifying adult asthma phenotypes using a cluster approach. *Eur Respir J* 2011; 38: 310–317.

35. Schatz M, Hsu JW, Zeiger RS, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. *J Allergy Clin Immunol* 2014; 133: 1549–1556.

36. Boudier A, Curjuric I, Basagaña X, et al. Ten year follow-up of cluster-based asthma phenotypes in adults. A pooled analysis of three cohorts. *Am J Respir Crit Care Med* 2013; 188: 550–560.

37. Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. *N Engl J Med* 2006; 354: 697–708.

38. Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. *Eur Respir J* 2011; 37: 1352–1359.

39. Jamieson KC, Warner SM, Leigh R, et al. Rhinovirus in the pathogenesis and clinical course of asthma. *Chest* 2015; 148: 1508–1516.